REGADENOSON

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H18N8O5.H2O
Molecular Weight	408.3693
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.CNC(=O)C1=CN(N=C1)C2=NC3=C(N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)C(N)=N2

InChI

InChIKey=CDQVVPUXSPZONN-WPPLYIOHSA-N

InChI=1S/C15H18N8O5.H2O/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14;/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21);1H2/t7-,9-,10-,14-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C15H18N8O5
Molecular Weight	390.354
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022161lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001176/WC500097103.pdf | https://ec.europa.eu/health/documents/community-register/2014/20140116127516/anx_127516_en.pdf | https://www.drugs.com/ppa/regadenoson.html

Regadenoson (Lexiscan), a low affinity agonist of the A2A adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries. It is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The most common adverse reactions to Lexiscan are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. Methylxanthines, e.g., caffeine and theophylline, may interfere with the activity of Lexiscan. Aminophylline may be used to attenuate severe and/or persistent adverse reactions to Lexiscan.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adenosine A1 receptor 50 Target ID: CHEMBL226 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022161lbl.pdf	Agonist 2678		16.0 µM [Ki]
Adenosine A2a receptor 30 Target ID: CHEMBL251 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022161lbl.pdf	Agonist 2678		1.3 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Radionuclide myocardial perfusion imaging 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022161lbl.pdf	Diagnostic		Approved 8429	LEXISCAN Approved Use Lexiscan® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress (1). Launch Date 2008

C_max

Value	Dose	Co-administered	Analyte	Population
13.6 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/20063904/	400 μg single, intravenous dose: 400 μg route of administration: Intravenous experiment type: SINGLE co-administered:		REGADENOSON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
11.7 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/20063904/	400 μg single, intravenous dose: 400 μg route of administration: Intravenous experiment type: SINGLE co-administered:		REGADENOSON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2 h REVIEW https://pubmed.ncbi.nlm.nih.gov/20063904/	400 μg single, intravenous dose: 400 μg route of administration: Intravenous experiment type: SINGLE co-administered:		REGADENOSON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Palpitation (3 patients) Flushing (3 patients) Shortness of breath (4 patients) Nausea and vomiting (5 patients) Change in ECG (1 patient) Headache (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211
10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Palpitation (3 patients) Dizziness (3 patients) Shortness of breath (1 patient) Nausea and vomiting (2 patients) Headache (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211
10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	Other AEs: Palpitation, Dizziness... Other AEs: Palpitation (4 patients) Dizziness (2 patients) Flushing (4 patients) Shortness of breath (2 patients) Change in ECG (1 patient) Headache (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211
20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (2 patients) Palpitation (2 patients) Dizziness (3 patients) Flushing (1 patient) Nausea and vomiting (4 patients) Headache (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211
20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Palpitation (4 patients) Dizziness (3 patients) Flushing (8 patients) Shortness of breath (3 patients) Nausea and vomiting (3 patients) Change in ECG (7 patients) Headache (7 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211
3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	Other AEs: Palpitation, Dizziness... Other AEs: Palpitation (2 patients) Dizziness (1 patient) Flushing (1 patient) Change in ECG (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211
3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211	Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Palpitation (2 patients) Dizziness (1 patient) Flushing (3 patients) Shortness of breath (1 patient) Change in ECG (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17112296/ Page: 1211

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C8 911 CYP2C19 1478	CYP 270

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022161s013lbl.pdf Page: 8.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022161s013lbl.pdf Page: 8.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022161s013lbl.pdf Page: 8.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022161s013lbl.pdf Page: 8.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022161s013lbl.pdf Page: 8.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022161s013lbl.pdf Page: 8.0	no
P-gp 1650	supressor 155 Sources: https://pubmed.ncbi.nlm.nih.gov/27043281/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022161s000_LEXISCAN_CLINPHARM&BIOPHARMR.pdf Page: 18.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022161s000_LEXISCAN_PHARMR.pdf Page: 4.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA00C6IU	https://www.aablocks.com/goods/Goods/detail?id=AA00C6IU
Aaron Chemicals	AR00C7AM	http://www.aaronchem.com/313348-27-5
AbMole Bioscience	M5924	http://www.abmole.com/products/regadenoson.html
Acadechem	ACDS-063067	http://www.acadechemical.com/product/137766
Ambinter	Amb24123241	http://www.ambinter.com/reference/24123241
ApexBio Technology	B5904	http://www.apexbt.com/regadenoson.html
BLD Pharm	BD305754	http://www.bldpharm.com/products/313348-27-5.html
BioCrick	BCC6438	http://www.biocrick.com/Regadenoson-BCC6438.html
BioSynth	J-018384	https://www.biosynth.com/en/products/all-products/products/J-018384.html
CSNpharm	CSN15960	https://www.csnpharm.com/products/regadenoson.html
Chem Scene	CS-5612	http://www.chemscene.com/313348-27-5.html
ChemMol	49419376	http://www.chemmol.com/chemmol/49419376.html
Chemspace	CSSB00020618037	https://chem-space.com/CSSB00020618037
Excenen	EX-A2148	https://www.excenen.com/searchresultlist.php?id=313348-27-5
Glentham Life Sciences	GP4974	http://www.glentham.com/products/product/GP4974/
Hairui	HR121254	http://www.hairuichem.com/en/product/313348-27-5.html
Lab Network	LN02195827	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN02195827
MedChem Express	HY-A0168	https://www.medchemexpress.com/Regadenoson.html
OChem	30700	http://www.ocheminc.com/index.php?act=psearch&pid=348R275
Sinfoo Biotech	S047410	http://www.sinfoobiotech.com/product/1050808
Smolecule	S572215	https://www.smolecule.com/products/s572215
THE BioTek	bt-305914	https://www.thebiotek.com/product/others/bt-305914
Wuhan Atomole Chemicals Co., Ltd.	AT-36942	http://www.atomole.com/en/products-view.asp?id=122825
Yuhao Chemical	RT18257	http://www.chemyuhao.com/313348-27-5.html
eNovation Chemicals	D501812	http://www.enovationchem.com/productDetails.asp?productID=D501812
eNovation Chemicals	D634242	https://www.enovationchem.com/ProductDetails.asp?ProductID=D634242
eNovation Chemicals	Y0973996	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0973996
iChemical	EBD21504	http://www.ichemical.com/chemicals/cas-313348-27-5

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

5 mL (0.4 mg) by rapid injection; followed immediately by saline flush and radiopharmaceutical.

Route of Administration: Intravenous

In Vitro Use Guide

10 nM CVT-3146 decreased coronary perfusion pressure by 23 mm Hg in rat isolated perfused heart.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:12:17 GMT 2023` Edited by `admin` on `Fri Dec 15 16:12:17 GMT 2023`
Record UNII	2XLN4Y044H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

REGADENOSON

Official Name

English

Regadenoson [WHO-DD]

Common Name

English

REGADENOSON MONOHYDRATE [MI]

Common Name

English

RAPISCAN

Brand Name

English

REGADENOSON [VANDF]

Common Name

English

REGADENOSON MONOHYDRATE [MART.]

Common Name

English

REGADENOSON MONOHYDRATE

Common Name

English

REGADENOSON [USAN]

Common Name

English

REGADENOSON HYDRATE [JAN]

Common Name

English

REGADENOSON [ORANGE BOOK]

Common Name

English

ADENOSINE, 2-(4-((METHYLAMINO)CARBONYL)-1H-PYRAZOL-1-YL)-, MONOHYDRATE

Systematic Name

English

REGADENOSON HYDRATE

Common Name

English

LEXISCAN

Brand Name

English

REGADENOSON [EMA EPAR]

Common Name

English

1-(6-AMINO-9-.BETA.-D-RIBOFURANOSYL-9H-PURIN-2-YL)-N-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE, MONOHYDRATE

Common Name

English

CVT-3146

Code

English

Classification Tree Code System Code

NDF-RT

N0000175788